The DOI matches its Crossref record; 192 of the 192 references it cites were found in a registry or an index.
DNA damage checkpoint kinases in cancer
Open accessAbstract
DNA damage response (DDR) pathway prevents high level endogenous and environmental DNA damage being replicated and passed on to the next generation of cells via an orchestrated and integrated network of cell cycle checkpoint signalling and DNA repair pathways. Depending on the type of damage, and where in the cell cycle it occurs different pathways are involved, with the ATM-CHK2-p53 pathway controlling the G1 checkpoint or ATR-CHK1-Wee1 pathway controlling the S and G2/M checkpoints. Loss of G1 checkpoint control is common in cancer through TP53, ATM mutations, Rb loss or cyclin E overexpression, providing a stronger rationale for targeting the S/G2 checkpoints. This review will focus on the ATM-CHK2-p53-p21 pathway and the ATR-CHK1-WEE1 pathway and ongoing efforts to target these pathways for patient benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors
Pires, I. M., Ward, T. H., & Dive, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00607.x · Cited by 29
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 2×
“Somatic TP53 mutations are observed in around 40% of all tumours (Refs 47, 48), the mutation rate varying between cancer types from nearly 100% in ovarian cancer to 10% for haematological malignancies (Ref.”
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Blackford, A. N., & Jackson, S. P. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.015 · Cited by 1,961
The ATM protein kinase: regulating the cellular response to genotoxic stress, and more
Shiloh, Y., & Ziv, Y. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3546 · Cited by 1,649
Liu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625
DNA Damage Sensing by the ATM and ATR Kinases
Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514
Repair Pathway Choices and Consequences at the Double-Strand Break
Ceccaldi, R., Rondinelli, B., & D’Andrea, A. D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.07.009 · Cited by 1,499
Atm-Deficient Mice: A Paradigm of Ataxia Telangiectasia
Barlow, C., Hirotsune, S., Paylor, R., Liyanage, M., Eckhaus, M., Collins, F., Shiloh, Y., Crawley, J. N., Ried, T., Tagle, D., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80086-0 · Cited by 1,458
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
G1 cell-cycle control and cancer
Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,224
Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220
Self-citationDouble-strand break repair: 53BP1 comes into focus
Panier, S., & Boulton, S. J. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3719 · Cited by 1,098
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks
Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C. M., Lukas, J., & Jackson, S. P. (2006) · Nature Cell Biology · doi:10.1038/ncb1337 · Cited by 1,064
(1999) · PubMed · Cited by 1,030
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
ATR disruption leads to chromosomal fragmentation and early embryonic lethality
Brown, E. J., & Baltimore, D. (2000) · Genes & Development · doi:10.1101/gad.14.4.397 · Cited by 951
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016600 · Cited by 869
The essential kinase ATR: ensuring faithful duplication of a challenging genome
Saldivar, J. C., Cortez, D., & Cimprich, K. A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.67 · Cited by 838
ATM Signaling Facilitates Repair of DNA Double-Strand Breaks Associated with Heterochromatin
Goodarzi, A. A., Noon, A. T., Deckbar, D., Ziv, Y., Shiloh, Y., Löbrich, M., & Jeggo, P. A. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.017 · Cited by 836
DNA Replication Stress as a Hallmark of Cancer
Macheret, M., & Halazonetis, T. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040424 · Cited by 823
Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
Sørensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuåsen, R. G., Lundin, C., Bartek, J., & Helleday, T. (2005) · Nature Cell Biology · doi:10.1038/ncb1212 · Cited by 666
Ataxia telangiectasia: a review
Rothblum-Oviatt, C., Wright, J., Lefton-Greif, M. A., McGrath-Morrow, S. A., Crawford, T. O., & Lederman, H. M. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0543-7 · Cited by 647
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
CHEK2 Is a Multiorgan Cancer Susceptibility Gene
Cybulski, C., Górski, B., Huzarski, T., Masojć, B., Mierzejewski, M., Dębniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/426403 · Cited by 551
Syljuåsen, R. G., Sørensen, C. S., Hansen, L. T., Fugger, K., Lundin, C., Johansson, F., Helleday, T., Sehested, M., Lukas, J., & Bartek, J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.9.3553-3562.2005 · Cited by 550
Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., & Piwnica-Worms, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5600 · Cited by 544
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
Cliby, W. A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.1.159 · Cited by 536
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Paull, T. T. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034335 · Cited by 460
CHK2 kinase in the DNA damage response and beyond
Zannini, L., Delia, D., & Buscemi, G. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju045 · Cited by 455
ATM Mutations in Cancer: Therapeutic Implications
Choi, M., Kipps, T., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0945 · Cited by 453
The p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice
de Klein, A., Muijtjens, M., van Os, R., Verhoeven, Y., Smit, B., Carr, A. M., Lehmann, A. R., & Hoeijmakers, J. H. J. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00447-4 · Cited by 443
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription
Takai, H., Naka, K., Okada, Y., Watanabe, M., Harada, N., Saito, S., Anderson, C. W., Appella, E., Nakanishi, M., Suzuki, H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf506 · Cited by 436
GermlineTP53 mutations and Li-Fraumeni syndrome
Varley, J. M. (2003) · Human Mutation · doi:10.1002/humu.10185 · Cited by 430
Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place
Kotsantis, P., Petermann, E., & Boulton, S. J. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1461 · Cited by 416
Zabludoff, S. D., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S., Caleb, B. L., Green, S., Haye, H. R., Horn, C. L., Janetka, J. W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0492 · Cited by 413
Dual roles of ATM in the cellular response to radiation and in cell growth control.
Xu, Y., & Baltimore, D. (1996) · Genes & Development · doi:10.1101/gad.10.19.2401 · Cited by 403
Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation
O'Connell, M. J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.3.545 · Cited by 398
Yazinski, S. A., Comaills, V., Buisson, R., Genois, M.-M., Nguyen, H. D., Ho, C. K., Todorova Kwan, T., Morris, R., Lauffer, S., Nussenzweig, A., et al. (2017) · Genes & Development · doi:10.1101/gad.290957.116 · Cited by 395
A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging
Murga, M., Bunting, S., Montaña, M. F., Soria, R., Mulero, F., Cañamero, M., Lee, Y., McKinnon, P. J., Nussenzweig, A., & Fernandez-Capetillo, O. (2009) · Nature Genetics · doi:10.1038/ng.420 · Cited by 340
Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5942 · Cited by 338
Foote, K. M., Nissink, J. W. M., McGuire, T., Turner, P., Guichard, S., Yates, J. W. T., Lau, A., Blades, K., Heathcote, D., Odedra, R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01187 · Cited by 332
Durant, S. T., Zheng, L., Wang, Y., Chen, K., Zhang, L., Zhang, T., Yang, Z., Riches, L., Trinidad, A. G., Fok, J. H. L., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat1719 · Cited by 309
Goodarzi, A. A., Jeggo, P., & Lobrich, M. (2010) · DNA Repair · doi:10.1016/j.dnarep.2010.09.013 · Cited by 305
Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294
Rapid Activation of ATR by Ionizing Radiation Requires ATM and Mre11
Myers, J. S., & Cortez, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513265200 · Cited by 292
Positive Regulation of Wee1 by Chk1 and 14-3-3 Proteins
Lee, J., Kumagai, A., & Dunphy, W. G. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.3.551 · Cited by 291
Kim, H., George, E., Ragland, R. L., Rafail, S., Zhang, R., Krepler, C., Morgan, M. A., Herlyn, M., Brown, E. J., & Simpkins, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2273 · Cited by 291
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Hallek, M. (2017) · American Journal of Hematology · doi:10.1002/ajh.24826 · Cited by 282
Deletions linked to TP53 loss drive cancer through p53-independent mechanisms
Liu, Y., Chen, C., Xu, Z., Scuoppo, C., Rillahan, C. D., Gao, J., Spitzer, B., Bosbach, B., Kastenhuber, E. R., Baslan, T., et al. (2016) · Nature · doi:10.1038/nature17157 · Cited by 279
Rajeshkumar, N. V., De Oliveira, E., Ottenhof, N., Watters, J., Brooks, D., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274
Rainey, M. D., Charlton, M. E., Stanton, R. V., & Kastan, M. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0763 · Cited by 266
Replication stress: getting back on track
Berti, M., & Vindigni, A. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3163 · Cited by 255
Double strand break repair functions of histone H2AX
Scully, R., & Xie, A. (2013) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2013.07.007 · Cited by 252
Spycher, C., Miller, E. S., Townsend, K., Pavic, L., Morrice, N. A., Janscak, P., Stewart, G. S., & Stucki, M. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200709008 · Cited by 244
Vendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O’Connor, M. J., & Bakkenist, C. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6247 · Cited by 239
Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11115 · Cited by 237
MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
Bridges, K. A., Hirai, H., Buser, C. A., Brooks, C., Liu, H., Buchholz, T. A., Molkentine, J. M., Mason, K. A., & Meyn, R. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0650 · Cited by 237
Somatic TP53 Mutations in the Era of Genome Sequencing
Hainaut, P., & Pfeifer, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026179 · Cited by 231
Targeting the ATR-CHK1 Axis in Cancer Therapy
Rundle, S., Bradbury, A., Drew, Y., & Curtin, N. (2017) · Cancers · doi:10.3390/cancers9050041 · Cited by 231
Self-citationZhang, Q., Green, M. D., Lang, X., Lazarus, J., Parsels, J. D., Wei, S., Parsels, L. A., Shi, J., Ramnath, N., Wahl, D. R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0761 · Cited by 226
Blasina, A., Hallin, J., Chen, E., Arango, M. E., Kraynov, E., Register, J., Grant, S., Ninkovic, S., Chen, P., Nichols, T., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2391 · Cited by 223
Melander, F., Bekker-Jensen, S., Falck, J., Bartek, J., Mailand, N., & Lukas, J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200708210 · Cited by 221
Hall-Jackson, C. A., Cross, D. A., Morrice, N., & Smythe, C. (1999) · Oncogene · doi:10.1038/sj.onc.1203077 · Cited by 215
Foote, K. M., Blades, K., Cronin, A., Fillery, S., Guichard, S. S., Hassall, L., Hickson, I., Jacq, X., Jewsbury, P. J., McGuire, T. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301859s · Cited by 214
ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
Biddlestone-Thorpe, L., Sajjad, M., Rosenberg, E., Beckta, J. M., Valerie, N. C. K., Tokarz, M., Adams, B. R., Wagner, A. F., Khalil, A., Gilfor, D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3408 · Cited by 213
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
Wang, Y., Li, J., Booher, R. N., Kraker, A. J., Lawrence, T. S., Leopold, W. R., & Sun, Y. (2001) · PubMed · Cited by 210
ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
Huntoon, C. J., Flatten, K. S., Wahner Hendrickson, A. E., Huehls, A. M., Sutor, S. L., Kaufmann, S. H., & Karnitz, L. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0110 · Cited by 202
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 199
Ou, Y.-H., Chung, P.-H., Sun, T.-P., & Shieh, S.-Y. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0689 · Cited by 198
Autophosphorylation and ATM Activation
Kozlov, S. V., Graham, M. E., Jakob, B., Tobias, F., Kijas, A. W., Tanuji, M., Chen, P., Robinson, P. J., Taucher-Scholz, G., Suzuki, K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.204065 · Cited by 197
Homologous recombination-mediated double-strand break repair
Wyman, C., Ristic, D., & Kanaar, R. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.037 · Cited by 195
Peasland, A., Wang, L.-Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., Cliby, W. A., Sarkaria, J., Beale, G., Edmondson, R. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.243 · Cited by 195
Self-citationCuneo, K. C., Morgan, M. A., Sahai, V., Schipper, M. J., Parsels, L. A., Parsels, J. D., Devasia, T., Al-Hawaray, M., Cho, C. S., Nathan, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00730 · Cited by 195
Sen, T., Tong, P., Stewart, C. A., Cristea, S., Valliani, A., Shames, D. S., Redwood, A. B., Fan, Y. H., Li, L., Glisson, B. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3409 · Cited by 194
Sausville, E., LoRusso, P., Carducci, M., Carter, J., Quinn, M. F., Malburg, L., Azad, N., Cosgrove, D., Knight, R., Barker, P., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2380-5 · Cited by 192
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
King, C., Diaz, H. B., McNeely, S., Barnard, D., Dempsey, J., Blosser, W., Beckmann, R., Barda, D., & Marshall, M. S. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1037 · Cited by 187
Chen, X., Niu, H., Chung, W.-H., Zhu, Z., Papusha, A., Shim, E. Y., Lee, S. E., Sung, P., & Ira, G. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2105 · Cited by 185
Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy
Bartucci, M., Svensson, S., Romania, P., Dattilo, R., Patrizii, M., Signore, M., Navarra, S., Lotti, F., Biffoni, M., Pilozzi, E., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.170 · Cited by 181
Coupling of Homologous Recombination and the Checkpoint by ATR
Buisson, R., Niraj, J., Rodrigue, A., Ho, C. K., Kreuzer, J., Foo, T. K., Hardy, E. J.-L., Dellaire, G., Haas, W., Xia, B., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.007 · Cited by 181
Checkpoint Kinase Inhibitors: SAR and Radioprotective Properties of a Series of 2-Arylbenzimidazoles
Arienti, K. L., Brunmark, A., Axe, F. U., McClure, K., Lee, A., Blevitt, J., Neff, D. K., Huang, L., Crawford, S., Pandit, C. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0495935 · Cited by 175
Jossé, R., Martin, S. E., Guha, R., Ormanoglu, P., Pfister, T. D., Reaper, P. M., Barnes, C. S., Jones, J., Charlton, P., Pollard, J. R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3369 · Cited by 172
Thomas, A., Redon, C. E., Sciuto, L., Padiernos, E., Ji, J., Lee, M.-J., Yuno, A., Lee, S., Zhang, Y., Tran, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6915 · Cited by 171
Batey, M. A., Zhao, Y., Kyle, S., Richardson, C., Slade, A., Martin, N. M. B., Lau, A., Newell, D. R., & Curtin, N. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0707 · Cited by 164
Self-citationMin, A., Im, S., Jang, H., Kim, S., Lee, M., Kim, D. K., Yang, Y., Kim, H. J., Lee, K.-H., Kim, J. W., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0378 · Cited by 163
The causes of replication stress and their consequences on genome stability and cell fate
Magdalou, I., Lopez, B. S., Pasero, P., & Lambert, S. A. E. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.04.035 · Cited by 161
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
Lee, S. B., Kim, S. H., Bell, D. W., Wahrer, D. C. R., Schiripo, T. A., Jorczak, M. M., Sgroi, D. C., Garber, J. E., Li, F. P., Nichols, K. E., et al. (2001) · PubMed · Cited by 160
Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
Karnak, D. M., Engelke, C. G., Parsels, L. A., Kausar, T., Wei, D., Robertson, J. R., Marsh, K. B., Davis, M. A., Zhao, L., Maybaum, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1038 · Cited by 158
Bártek, J., Lukas, J., & Bártková, J. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4754 · Cited by 154
Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
Sanjiv, K., Hagenkort, A., Calderón‐Montaño, J. M., Koolmeister, T., Reaper, P. M., Mortusewicz, O., Jacques, S. A., Kuiper, R., Schultz, N., Scobie, M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.12.032 · Cited by 149
Bukhari, A. B., Lewis, C. W., Pearce, J. J., Luong, D., Chan, G. K. T., & Gamper, A. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122622 · Cited by 143
Pike, K. G., Barlaam, B. C., Cadogan, E. B., Campbell, A. D., Chen, Y., Colclough, N., Davies, N. L., de-Almeida, C., Degorce, S. L., Didelot, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01896 · Cited by 138
Defect in Multiple Cell Cycle Checkpoints in Ataxia-Telangiectasia Postirradiation
Beamish, H., Williams, R. T., Chen, P., & Lavin, M. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20486 · Cited by 137
DNA replication stress and cancer chemotherapy
Kitao, H., Iimori, M., Kataoka, Y., Wakasa, T., Tokunaga, E., Saeki, H., Oki, E., & Maehara, Y. (2017) · Cancer Science · doi:10.1111/cas.13455 · Cited by 136
Parsels, L. A., Karnak, D. M., Parsels, J. D., Zhang, Q., Vélez-Padilla, J., Reichert, Z. R., Wahl, D. R., Maybaum, J., O’Connor, M. J., Lawrence, T. S., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0455 · Cited by 135
ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells
Ronco, C., Martin, A. R., Demange, L., & Benhida, R. (2016) · MedChemComm · doi:10.1039/c6md00439c · Cited by 134
11q deletion in neuroblastoma: a review of biological and clinical implications
Mlakar, V., Mlakar, S. J., López, G., Maris, J. M., Ansari, M., & Gumy‐Pause, F. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0686-8 · Cited by 134
Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
Ferrao, P. T., Bukczynska, E. P., Johnstone, R. W., & McArthur, G. A. (2012) · Oncogene · doi:10.1038/onc.2011.358 · Cited by 133
Loss of ATM accelerates pancreatic cancer formation and epithelial–mesenchymal transition
Russell, R., Perkhofer, L., Liebau, S., Lin, Q., Lechel, A., Feld, F. M., Heßmann, E., Gaedcke, J., Güthle, M., Zenke, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8677 · Cited by 133
Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
Russell, M. R., Levin, K., Rader, J., Belcastro, L. T., Li, Y., Martínez, D., Pawel, B., Shumway, S. D., Maris, J. M., & Cole, K. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2669 · Cited by 130
Gadhikar, M. A., Sciuto, M. R., Alves, M. V. O., Pickering, C. R., Osman, A. A., Neskey, D. M., Zhao, M., Fitzgerald, A. L., Myers, J. N., & Frederick, M. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0157 · Cited by 129
Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
Dillon, M. T., Barker, H. E., Pedersen, M., Hafsi, H., Bhide, S. A., Newbold, K. L., Nutting, C. M., McLaughlin, M., & Harrington, K. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0239 · Cited by 129
Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination
Krajewska, M., Heijink, A. M., Bisselink, Y., Seinstra, R. I., Silljé, H. H. W., de Vries, E. G. E., & van Vugt, M. A. T. M. (2012) · Oncogene · doi:10.1038/onc.2012.296 · Cited by 126
MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
Kreahling, J. M., Gemmer, J. Y., Reed, D. R., Letson, D. G., Bui, M. M., & Altiok, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0529 · Cited by 125
ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
Wang, C., Jette, N., Moussienko, D., Bebb, D. G., & Lees‐Miller, S. P. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.01.007 · Cited by 125
WEE1 inhibition sensitizes osteosarcoma to radiotherapy
PosthumaDeBoer, J., Würdinger, T., Graat, H. C. A., van Beusechem, V. W., Helder, M. N., van Royen, B. J., & Kaspers, G. J. L. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-156 · Cited by 121
Bryant, C., Rawlinson, R., & Massey, A. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-570 · Cited by 119
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Jiang, X., Li, W., Li, X., Bai, H., & Zhang, Z. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200524 · Cited by 116
Anderson, V. E., Walton, M. I., Eve, P. D., Boxall, K. J., Antoni, L., Caldwell, J., Aherne, W., Pearl, L. H., Oliver, A. W., Collins, I., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1252 · Cited by 114
Sarcar, B., Kahali, S., Prabhu, A. H., Shumway, S. D., Xu, Y., Demuth, T., & Chinnaiyan, P. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0469 · Cited by 110
ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma
Schmitt, A., Knittel, G., Welcker, D., Yang, T.-P., George, J., Nowak, M., Leeser, U., Büttner, R., Perner, S., Peifer, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3398 · Cited by 110
Directing the use of DDR kinase inhibitors in cancer treatment
Brandsma, I., Fleuren, E. D. G., Williamson, C. T., & Lord, C. J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1389895 · Cited by 109
Mohni, K. N., Thompson, P. S., Luzwick, J. W., Glick, G. G., Pendleton, C. S., Lehmann, B. D., Pietenpol, J. A., & Cortez, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125482 · Cited by 108
Teng, P.-N., Bateman, N. W., Darcy, K. M., Hamilton, C. A., Maxwell, G. L., Bakkenist, C. J., & Conrads, T. P. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.12.035 · Cited by 104
ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Tu, X., Kahila, M. M. H., Zhou, Q., Yu, J., Kalari, K. R., Wang, L., Harmsen, W. S., Yuan, J., Boughey, J. C., Goetz, M. P., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0470 · Cited by 101
DNA repair defects and implications for immunotherapy
Bever, K. M., & Le, D. T. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122010 · Cited by 101
Jobson, A. G., Lountos, G. T., Lorenzi, P. L., Llamas, J., Connelly, J., Cerna, D., Tropea, J. E., Onda, A., Zoppoli, G. M., Kondapaka, S. B., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154997 · Cited by 100
ATR Is Not Required for p53 Activation but Synergizes with p53 in the Replication Checkpoint
Nghiem, P., Park, P. K., Kim, Y.-S., Desai, B. N., & Schreiber, S. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106113200 · Cited by 99
Panek, R. L., Lu, G. H., Klutchko, S. R., Batley, B. L., Dahring, T. K., Hamby, J. M., Hallak, H., Doherty, A. M., & Keiser, J. A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37140-x · Cited by 96
Walton, M. I., Eve, P. D., Hayes, A., Valenti, M. R., Brandon, A. K. D. H., Box, G., Hallsworth, A., Smith, E. L., Boxall, K. J., Lainchbury, M. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1322 · Cited by 94
Tominaga, Y., Li, C., Wang, R., & Deng, C. (2006) · International Journal of Biological Sciences · doi:10.7150/ijbs.2.161 · Cited by 93
Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.
Rabik, C., Njoku, M., & Dolan, M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.03.004 · Cited by 92
The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery
Chow, J. P. H., & Poon, R. Y. C. (2012) · Oncogene · doi:10.1038/onc.2012.504 · Cited by 91
Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair
Bence, A. K., McNeely, S., & Beckmann, R. P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0083 · Cited by 91
Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Jin, J., Fang, H., Yang, F., Ji, W., Guan, N., Sun, Z., Shi, Y., Zhou, G., & Guan, X. (2018) · Neoplasia · doi:10.1016/j.neo.2018.03.003 · Cited by 91
Carlessi, L., Buscemi, G., Larson, G., Hong, Z., Wu, J. Z., & Delia, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0567 · Cited by 89
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
Isono, M., Hoffmann, M. J., Pinkerneil, M., Sato, A., Michaelis, M., Cinatl, J. J., Niegisch, G., & Schulz, W. A. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0473-1 · Cited by 86
Brill, E., Yokoyama, T., Nair, J. R., Yu, M., Ahn, Y.-R., & Lee, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22195 · Cited by 82
Chaudhuri, L., Vincelette, N. D., Koh, B. D., Naylor, R. M., Flatten, K. S., Peterson, K. L., McNally, A., Gojo, I., Karp, J. E., Mesa, R. A., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.093187 · Cited by 80
Zhou, Z., Yang, Z., Wang, S.-J., Zhang, L., Luo, J., Feng, Y., Yu, X., Chen, X., & Guo, X. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.136 · Cited by 79
Montano, R. E., Thompson, R. H., Chung, I., Hou, H. G., Khan, N. I., & Eastman, A. R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-604 · Cited by 77
Ouillette, P. D., Fossum, S., Parkin, B. L., Ding, L., Bockenstedt, P. L., Al-Zoubi, A., Shedden, K., & Malek, S. N. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2534 · Cited by 73
Karlin, J. D., Allen, J., Ahmad, S. F., Hughes, G. D., Sheridan, V. H., Odedra, R., Farrington, P. M., Cadogan, E. B., Riches, L. C., Garcia-Trinidad, A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0975 · Cited by 72
Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network
Greenberg, R. A. (2008) · Chromosoma · doi:10.1007/s00412-008-0154-8 · Cited by 70
Middleton, F. K., Patterson, M. J., Elstob, C. J., Fordham, S. E., Herriott, A., Wade, M., McCormick, A., Edmondson, R. J., May, F. E. B., Allan, J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6136 · Cited by 70
Self-citationLowery, C. D., VanWye, A. B., Dowless, M. S., Blosser, W. D., Falcón, B. L., Stewart, J. A., Stephens, J. R., Beckmann, R. P., Bence, A. K., & Stancato, L. F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2876 · Cited by 70
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
Chilà, R., Basana, A., Lupi, M., Guffanti, F., Gaudio, E., Rinaldi, A., Cascione, L., Restelli, V., Tarantelli, C., Bertoni, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2583 · Cited by 63
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells
Booth, L. A., Cruickshanks, N. A., Ridder, T. S., Dai, Y., Grant, S., & Dent, P. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24424 · Cited by 62
Heijink, A. M., Blomen, V. A., Bisteau, X., Degener, F., Matsushita, F. Y., Kaldis, P., Foijer, F., & van Vugt, M. A. T. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505283112 · Cited by 62
Hsu, W., Zhao, X., Zhu, J., Kim, I., Rao, G., McCutcheon, J. N., Hsu, S.-T., Teicher, B. A., Kallakury, B., Dowlati, A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.028 · Cited by 62
Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
Xiao, Y., Ramiscal, J. A. B., Kowanetz, K., Nagro, C. J. D., Malek, S., Evangelista, M., Blackwood, E. R., Jackson, P. K., & O’Brien, T. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0404 · Cited by 61
Ma, J., Li, X., Su, Y., Zhao, J., Luedtke, D. A., Epshteyn, V., Edwards, H. J., Wang, G., Wang, Z., Chu, R. L., et al. (2017) · Scientific Reports · doi:10.1038/srep41950 · Cited by 61
Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel
Lewis, C. W., Jin, Z., Macdonald, D., Wei, W., Qian, X. J., Choi, W. S., He, R., Sun, X., & Chan, G. K. T. (2017) · Oncotarget · doi:10.18632/oncotarget.17848 · Cited by 61
Zhang, C., Yan, Z., Painter, C. L., Zhang, Q., Chen, E., Arango, M. E., Kuszpit, K. K., Zasadny, K. R., Hallin, M. E., Hallin, J. F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3272 · Cited by 60
Hauge, S., Naucke, C., Hasvold, G., Joel, M., Rødland, G. E., Juzenas, P., Stokke, T., & Syljuåsen, R. G. (2016) · Oncotarget · doi:10.18632/oncotarget.14089 · Cited by 57
Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo
Niida, H., Murata, K., Shimada, M., Ogawa, K., Ohta, K., Suzuki, K., Fujigaki, H., Khaw, A. K., Banerjee, B., Hande, M. P., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.218 · Cited by 56
Shi, Q. W., Shen, L., Dong, B., Fu, H., Kang, X., Yang, Y., Dai, L. X., Yan, W., Xiong, H., Liang, Z., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.010 · Cited by 53
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer.
Yin, Y., Shen, Q., Zhang, P., Tao, R., Chang, W., Li, R., Xie, G., Liu, W., Zhang, L., Kapoor, P., et al. (2017) · PubMed · Cited by 51
Magnussen, G. I., Emilsen, E., Fleten, K. G., Engesæter, B. Ø., Nähse, V., Fjær, R., Slipicevic, A., & Flørenes, V. A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1474-8 · Cited by 50
11q Deletions in Hematological Malignancies
Monni, O. M., & Knuutila, S. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109057924 · Cited by 49
Caldwell, J., Welsh, E. J., Matijssen, C., Anderson, V. E., Antoni, L., Boxall, K. J., Urban, F., Hayes, A., Raynaud, F. I., Rigoreau, L. J. M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101150b · Cited by 49
Fujisawa, H., Nakajima, N. I., Sunada, S., Lee, Y., Hirakawa, H., Yajima, H., Fujimori, A., Uesaka, M., & Okayasu, R. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0464-y · Cited by 48
Leszczyńska, K. B., Dobrynin, G., Leslie, R. E., Ient, J., Boumelha, A. J., Senra, J. M., Hawkins, M., Maughan, T., Mukherjee, S., & Hammond, E. M. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.10.023 · Cited by 48
ATM protein is deficient in over 40% of lung adenocarcinomas
Villaruz, L. C., Jones, H., Đačić, S., Abberbock, S. R., Kurland, B. F., Stabile, L. P., Siegfried, J. M., Conrads, T. P., Smith, N. R., O’Connor, M. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9757 · Cited by 47
Fordham, S. E., Blair, H. J., Elstob, C. J., Plummer, R., Drew, Y., Curtin, N. J., Heidenreich, O. T., Pal, D., Jamieson, D., Park, C., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015214 · Cited by 47
Self-citationAlsubhi, N. H., Middleton, F. K., Abdel-Fatah, T. M. A., Stephens, P., Doherty, R. E., Arora, A., Moseley, P. M., Chan, S. Y. T., Aleskandarany, M. A., Green, A. R., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.09.009 · Cited by 45
Self-citationBusch, C., Kriegs, M., Laban, S. A., Tribius, S., Knecht, R., Petersen, C., Dikomey, E., & Rieckmann, T. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.035 · Cited by 42
di Rorà, A. G. L., Iacobucci, I., Imbrogno, E., Papayannidis, C., Derenzini, E., Ferrari, A., Guadagnuolo, V., Robustelli, V., Parisi, S., Sartor, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10535 · Cited by 41
Abdel-Fatah, T. M. A., Arora, A., Alsubhi, N. H., Agarwal, D., Moseley, P. M., Perry, C., Doherty, R. E., Chan, S. Y. T., Green, A. R., Rakha, E. A., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.09.009 · Cited by 40
Xu, H., Cheung, I. Y., Wei, X. X., Tran, H., Gao, X., & Cheung, N. V. (2010) · International Journal of Cancer · doi:10.1002/ijc.25842 · Cited by 40
Common motifs in ETAA1 and TOPBP1 required for ATR kinase activation
Thada, V., & Cortez, D. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008154 · Cited by 40
Weber, A. M., Drobnitzky, N., Devery, A., Bokobza, S., Adams, R., Maughan, T., & Ryan, A. J. (2016) · Oncotarget · doi:10.18632/oncotarget.11845 · Cited by 39
Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study
Laake, K., Launonen, V., Niederacher, D., Gudlaugsdottir, S., Seitz, S., Rio, P. G., Champ�me, M.-H., Bièche, I., Birnbaum, D., White, G. R. M., et al. (1999) · Genes Chromosomes and Cancer · Cited by 37
MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells
Bridges, K. A., Chen, X., Liu, H., Rock, C. D., Buchholz, T. A., Shumway, S. D., Skinner, H. D., & Meyn, R. E. (2016) · Oncotarget · doi:10.18632/oncotarget.12311 · Cited by 37
Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity
Dohmen, A. J. C., Qiao, X., Duursma, A. M., Wijdeven, R. H. M., Lieftink, C., Hageman, F., Morris, B., Halonen, P., Vens, C., van den Brekel, M. W. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18034 · Cited by 37
Suzuki, M., Yamamori, T., Bo, T., Sakai, Y., & Inanami, O. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.04.002 · Cited by 37
Raso, A., Vecchio, D., Cappelli, E., Ropolo, M., Poggi, A. D., Nozza, P., Biassoni, R., Mascelli, S., Capra, V., Kalfas, F., et al. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00566.x · Cited by 35
Oza, A. M., Weberpals, J. I., Provencher, D. M., Grischke, E., Hall, M., Uyar, D. S., Estevez-Diz, M. D. P., Marmé, F., Kuzmin, A., Rosenberg, P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5506 · Cited by 35
Nagel, R., Avelar, A. T., Aben, N., Proost, N., van de Ven, M., van der Vliet, J., Cozijnsen, M., de Vries, H., Wessels, L. F. A., & Berns, A. J. M. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0972 · Cited by 35
Petersen, L. F., Klimowicz, A. C., Otsuka, S., Elegbede, A. A., Petrillo, S. K., Williamson, T. S., Williamson, C. T., Konno, M., Lees‐Miller, S. P., Hao, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16215 · Cited by 32
Liu, S., Ge, Y., Wang, T., Edwards, H. J., Ren, Q., Jiang, Y., Quan, C., & Wang, G. (2017) · Oncology Reports · doi:10.3892/or.2017.5580 · Cited by 31
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells
Booth, L. A., Roberts, J. L., Poklepovic, A. S., & Dent, P. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1472189 · Cited by 31
Herůdková, J., Paruch, K., Khirsariya, P., Souček, K., Krkoška, M., Blanářová, O. V., Sova, P., Kozubík, A., & Vaculová, A. H. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.002 · Cited by 28
Kurmasheva, R. T., Kurmashev, D., Reynolds, C. P., Kang, M. H., Wu, J., Houghton, P. J., & Smith, M. A. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26825 · Cited by 27
Samadder, P., Suchánková, T., Hylse, O., Khirsariya, P., Nikulenkov, F., Drápela, S., Straková, N., Vaňhara, P., Vašíčková, K., Kolářová, H., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0018 · Cited by 25
Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736
Restelli, V., Chilà, R., Lupi, M., Rinaldi, A., Kwee, I., Bertoni, F., Damia, G. L. M., & Carrassa, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5954 · Cited by 23
Nguyen, T., Hawkins, E., Kolluri, A., Kmieciak, M., Park, H., Lin, H., & Grant, S. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.10.009 · Cited by 17
KIM, J.-Y., Choi, H., Lee, H., Shin, J., SHIN, D.-H., Choi, J., Lee, Y. S., & Lee, K. (2015) · Oncology Reports · doi:10.3892/or.2015.3871 · Cited by 14
Šalovská, B., Janečková, H., Fabrik, I., Karlíková, R., Čecháková, L., Ondrej, M., Link, M., Friedecký, D., & Tichý, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199349 · Cited by 14
ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors
de Gooijer, M. C., Buil, L. C. M., Beijnen, J. H., & van Tellingen, O. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0539-8 · Cited by 9
(1995) · PubMed
Cited by
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Abuetabh, Y., Wu, H. H., Chai, C., Al Yousef, H., Persad, S., Sergi, C. M., & Leng, R. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00863-4 · Cited by 272
Aflatoxin B1: metabolism, toxicology, and its involvement in oxidative stress and cancer development
Cao, W., Yu, P., Yang, K., & Cao, D. (2022) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2021.2021339 · Cited by 255
Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C. (2022) · Cancers · doi:10.3390/cancers14194874 · Cited by 62
G2 arrest primes hematopoietic stem cells for megakaryopoiesis
Garyn, C. M., Bover, O., Murray, J. W., Ma, J., Salas-Briceno, K., Ross, S. R., & Snoeck, H.-W. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114388 · Cited by 14
Metadata
- Authors
- Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J.
- Venue
- Expert Reviews in Molecular Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2020
- Volume
- 22
- Pages
- e2-e2
- ISSN
- 1462-3994 (ISSN-L)
- OpenAlex
- W3032979845
- Cited by
- 322
- References
- 192
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.